Anti-KIT antibody, barzolvolimab, reduces skin mast cells and disease activity in chronic inducible urticaria.
Dorothea Terhorst-MolawiTomasz HawroEva GrekowitzLea KieferKunal MerchantDiego AlvaradoLawrence J ThomasThomas HawthorneElizabeth CrowleyMargo Heath-ChiozziMartin MetzMarcus MaurerPublished in: Allergy (2022)
In CIndU patients, barzolvolimab was well tolerated, demonstrated marked, rapid, durable depletion of skin MCs, circulating tryptase, and reductions in clinical activity with significant improvements in disease control and quality of life (QoL) demonstrating potential therapeutic effects for MC-mediated disorders.